IN THE CLAIMS:

Please cancel claims 8 and 9 without prejudice. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently Amended) A cyclic tetrapeptide derivative ~~comprising a~~ represented by the following general formula ~~selected from the group consisting of~~ (I), (I'), (I''), (I''') ~~and~~ or a pharmaceutically acceptable salt thereof:



(I)



(I')



(I")



(I''')

wherein each of R_{11}, R_{12}, R_{21} and R_{22} independently denotes hydrogen, a linear C_1-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached, or a branched C_3-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached; and

each of R_1, R_2 and R_3 independently denotes a linear C_1-C_5-alkylene group which may have a C_1-C_6 side chain, in which the side chain may form a condensed ring structure on the alkylene chain;

provided that at least one of R_{11}, R_{12}, R_{21} and R_{22} in general formula (I''') is a cyclohexyl methyl group.

2. (Previously Presented) The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I), or a pharmaceutically acceptable salt thereof.

3. (Previously Presented) The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I'), or a pharmaceutically acceptable salt thereof.

4. (Previously Presented) The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I''), or a pharmaceutically acceptable salt thereof.

5. (Previously Presented) The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I'''), or a pharmaceutically acceptable salt thereof.

Claims 6-9 (Canceled).

10. (Currently Amended) A method of inhibiting a histone deacetylase comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof as set forth in claim 1, thereby inhibiting a histone deacetylase ~~inhibitor~~.

11. (Previously Presented) A method of promoting an expression of an MHC class I molecule comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof as set forth in claim 1, thereby promoting an expression of an MHC class I molecule.

12. (New) A composition comprising a pharmaceutically acceptable carrier in combination with the cyclic tetrapeptide derivative according to claim 1 in an amount effective to inhibit growth of tumor cells.